High SLFN11 was also predictive of improved PFS and OS in 45 and 57 SCLC patients, respectively, with clinical follow-up, who had been treated with any chemotherapy; SLFN11 high median PFS 48.7 months and OS 40.2 months, SLFN11 low median PFS 10.3 months and OS 13.9 months (PFS P = 0.017 and OS P = 0.020) (Fig. 3g, h and Supplementary Tables 6 and,  7). Here, SLFN11 is linked to small cell lung carcinoma.